Article
LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib.
International journal of molecular sciences - 12 Apr 2023
Ruiz-Demoulin Salomé, Trenquier Eva, Dekkar Sanaa, Deshayes Sébastien, Boisguérin Prisca, Serrano César, de Santa Barbara Pascal, Faure Sandrine
Abstract excerpt
Gastrointestinal stromal tumor (GIST), the most common sarcoma, is mainly caused by an oncogenic mutation in the KIT receptor tyrosine kinase. Targeting KIT using tyrosine kinase inhibitors, such as imatinib and sunitinib, provides substantial benefit; however, in most patients, the disease will eventually progress due to KIT secondary mutations leading to treatment failure. Understanding how GIST cells initially...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.